Family counseling improves lives of patients and spouses coping with prostate cancer

November 12, 2007

Families coping with prostate cancer report improved quality of life from a structured support program integrated into the patient's cancer management, according to a new study. The findings appear in the December 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society. This randomized clinical trial by Dr. Laurel Northouse from the University of Michigan and co-investigators found that patients and their spouses who participated in a five-session home counseling program reported significant improvement in such areas as symptom management, hope, uncertainty and couples' communication.

Prostate cancer is the most frequently diagnosed cancer in men. While treatment advances have reduced mortality rates since the early 1990s, the treatments themselves are often associated with serious permanent side effects, such as urinary incontinence or sexual dysfunction. These side effects have been shown to impact both the patient and his spouse, who is most often solely relied upon to provide support and home care. Studies show that spouses of prostate cancer patients report greater levels of distress and uncertainty than their husbands and that couples report difficulties in communication. The stress of providing care for a loved one has been linked to poorer health and even higher risk of death.

Dr. Northouse and her colleagues conducted a randomized control trial comparing standard patient-centered clinical care and an intensive multivariable intervention targeting patients and their spouses. This family-based intervention targeted
  1. so-called "appraisal variables" - that is appraisal of illness or caregiving, uncertainty, hopelessness
  2. "coping resources" - such as coping strategies, self-efficacy, and communication
  3. overall or cancer-specific "symptom distress" and
  4. quality of life.


In Dr. Northouse's clinical trial, 113 couples were assigned to the control group and 112 to the intervention. Couples in the intervention group received three 90-minute sessions at home and two follow-up telephone sessions over a four-month period. Couples were then assessed before treatment and every four months for one year.

Spouses in the intervention arm reported the most benefits and most sustained improvements "that improved spouses' appraisal of the caregiving experience, increased their ability to cope, and enhanced their physical and mental quality of life." For example, spouses in the intervention arm reported significantly better mental health by the fourth month and significantly improved physical quality of life by the eighth month.

Based on their findings, Dr. Northouse and co-authors conclude that by employing a structured and systematic program conducted "jointly with patients and spouses, clinicians can help both to gain information and obtain support, which reduces their uncertainty and facilitates communication about the illness." At a minimum, they conclude, "clinicians need to recognize that spouses are affected by the cancer and to treat them as co-recipients of care."
-end-
Article: "Randomized Clinical Trial of a Family Intervention for Prostate Cancer Patients and Their Spouses," Laurel L. Northouse, Darlene W. Mood, Ann Schafenacker, James E. Montie, Howard M. Sandler, Jeffrey D. Forman, Maha Hussain, Kenneth J. Pienta, David C. Smith, Trace Kershaw, CANCER; Published Online: November 12, 2007 (DOI: 10.1002/cncr.23114); Print Issue Date: December 15, 2007.

Contact: Nicole Fawcett, University of Michigan, 734-764-2220, nfawcett@umich.edu

Wiley

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.